Pancreatic ductal adenocarcinoma(PDAC)is still a devastating disease,and for those who treat PDAC patients it sometimes seems that there is little to no relevant progress.The excellent new ESMO clinical practice guide...Pancreatic ductal adenocarcinoma(PDAC)is still a devastating disease,and for those who treat PDAC patients it sometimes seems that there is little to no relevant progress.The excellent new ESMO clinical practice guideline by Conroy et al.(1)points to important advances in pancreatic cancer therapy that were made since the previous edition from 2015(2).According to the American Cancer Society the overall five-year survival for all stages of PDAC has improved from 5%some 30 years ago to 13%in the present day.The major thrust lies in greatly improved outcomes for resectable pancreatic cancer with 5-year survival increasing from 5-10%at the beginning of this period to 30-50%due to technical improvements in surgery along with combination adjuvant chemotherapy.展开更多
Interdisciplinary perioperative treatment has greatly improved the outcome of pancreatic cancer patients.Based on randomized,controlled phase III clinical trials,adjuvant chemotherapy with mFOLFIRINOX(PRODIGE-24 study...Interdisciplinary perioperative treatment has greatly improved the outcome of pancreatic cancer patients.Based on randomized,controlled phase III clinical trials,adjuvant chemotherapy with mFOLFIRINOX(PRODIGE-24 study),gemcitabine/capecitabine(ESPAC-4)or 5-fluorouracil/gemcitabine monotherapy(ESPAC-1,CONKO-001,ESPAC-3)is now the clinical standard after curative resection(1).展开更多
文摘Pancreatic ductal adenocarcinoma(PDAC)is still a devastating disease,and for those who treat PDAC patients it sometimes seems that there is little to no relevant progress.The excellent new ESMO clinical practice guideline by Conroy et al.(1)points to important advances in pancreatic cancer therapy that were made since the previous edition from 2015(2).According to the American Cancer Society the overall five-year survival for all stages of PDAC has improved from 5%some 30 years ago to 13%in the present day.The major thrust lies in greatly improved outcomes for resectable pancreatic cancer with 5-year survival increasing from 5-10%at the beginning of this period to 30-50%due to technical improvements in surgery along with combination adjuvant chemotherapy.
文摘Interdisciplinary perioperative treatment has greatly improved the outcome of pancreatic cancer patients.Based on randomized,controlled phase III clinical trials,adjuvant chemotherapy with mFOLFIRINOX(PRODIGE-24 study),gemcitabine/capecitabine(ESPAC-4)or 5-fluorouracil/gemcitabine monotherapy(ESPAC-1,CONKO-001,ESPAC-3)is now the clinical standard after curative resection(1).
